Following on from a previous post on Sean Parker’s cancer initiative – the Parker Institute for Cancer Immunotherapy (PICI) – Fortune Magazine recently published an expansive piece on the thinking behind it and the challenges faced by this and other initiatives in advancing immunotherapy as a cancer treatment.
Pascal Hughes CEO of Levrett Plc (LON:LVRT) spoke with DirectorsTalk about this and said: While PICI is not without it’s doubters, the collaboration of six of the US leading cancer centers will be watched closely not just in the US, but here in the UK also. As the article states..” With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their efforts on planning clinical trials in immunotherapy, recruit patients quickly, and share the information learned—which could be the single biggest factor in speeding up drug development.”
Levrett plc is a special purpose acquisition company formed to acquire realisable and/or developed commercial technologies focused in the Pharmaceutical and Biotechnology sector. The Company draws on its expertise in the Pharmaceutical and Biotechnology sector to assess different propositions and initiate discussions via market contacts and professional advisers. In selecting acquisition opportunities to review, the Board will focus on entities that are available at attractive valuations and hold opportunities to unlock embedded value. Once an acquisition target has been identified the Company will carry out a comprehensive and thorough project review process in which all material aspects of a potential project or business will be subject to rigorous due diligence, as appropriate.
